AIM VACCINE CO., LTD.
AIM Vaccine Co., Ltd. (Stock Code: 06660.HK) is a Hong Kong-listed company established on November 9, 2011, with a unified social credit code of 91210100583868927X and a total share capital of 1.211 billion RMB. The company's registered address is Room 412, 4th Floor, Building 6, No. 105, Jinghai 3rd Road, Beijing Economic and Technological Development Zone, Beijing.
As one of China's leading vaccine companies, AIM Vaccine covers the entire value chain from R&D, manufacturing, to commercialization. Committed to producing conscientious vaccines for the health of all, it is the second-largest and the largest private full-industrial-chain vaccine group in China, as well as a leading enterprise in the Chinese vaccine sector, with a mature and self-innovated mRNA technology platform.
AIM Vaccine owns four fully controlled licensed vaccine manufacturing companies, three vaccine research institutes, and four R&D centers, with seven R&D teams ensuring milestone delivery for its product pipeline. It is one of only two Chinese human vaccine companies with P3 laboratory strategic resources. AIM is also the largest global manufacturer of hepatitis B vaccines and the second-largest global rabies vaccine manufacturer.
The company has five validated vaccine technology platforms, offering eight commercialized vaccines and 20 vaccines under development. Its pipeline covers the top 10 global vaccine products. AIM’s commercialized products maintain market leadership and are sold across all 31 provinces, cities, and autonomous regions in China, reaching over 2,800 district and county CDCs. AIM Vaccine is a rare, comprehensive platform with advantages in pipeline, R&D, manufacturing, and sales.
Product Category
Source premium vaccines: Bulk Hepatitis B, Rabies, Meningococcal ACYW135, and Hepatitis A from our GMP factories – featuring cold-chain stability and export-ready packaging.
AIM Honor (Ningbo) Biopharmaceutical Co., Ltd. is a manufacturer and supplier of Freeze-Dried Rabies Vaccine Vero Cell for Human Use. We support bulk purchasing and cross-border supply of products to provide safe and effective vaccine products to customers worldwide.
What is a Rabies Vaccine?
A rabies vaccine is a biological product used to prevent rabies virus infection. It stimulates the body to produce specific antibodies that neutralize the invading rabies virus, reducing the risk of illness (the fatality rate of rabies is almost 100%, and vaccination is the key preventive measure).
Usage History
The rabies vaccine was invented by the French scientist Louis Pasteur in 1885. It was first used on Joseph Meister, a 9-year-old boy bitten by a rabid dog, successfully saving the lucky child's life—this is the earliest recorded use of the rabies vaccine in human history.
In the mid-20th century, inactivated rabies vaccines were developed, addressing the safety issues of attenuated live vaccines and becoming the mainstream for human use.
In the 1980s, with the rise of genetic engineering technology, recombinant rabies vaccines entered the research and development phase, and were gradually marketed in the 1990s, further improving safety and immunogenicity.
To date, inactivated vaccines remain the global mainstream for human use, while genetically engineered vaccines are rapidly gaining popularity due to their advantages. The "five-dose schedule" and "2-1-1 schedule" have become standardized vaccination procedures for post-exposure prophylaxis.
Classification (by Technical Route)
Inactivated Vaccine: The mainstream type, made from inactivated rabies virus strains. It features high safety and stable immunogenicity, suitable for both humans and animals.
Attenuated Live Vaccine: Produced by weakening the virulence of the rabies virus. It has strong immunogenicity but slightly lower safety than inactivated vaccines, and is mostly used for animal immunization (rarely for human use in some regions).
Genetically Engineered Vaccine: Expresses viral antigens (such as glycoprotein G) through genetic recombination technology. It has high purity, mild side effects, and is a development direction in recent years (e.g., CHO cell-expressed vaccines).
Key Differences Between Different Types of Rabies Vaccines
| Vaccine Type | Core Components | Common Packaging Specifications | Core Features | Application Scenarios |
| Inactivated Vaccine (Human) | Inactivated rabies virus (e.g., PV strain, CTN-1V strain) | 1ml/vial (single dose), 2ml/vial (double dose) | High safety, long antibody duration (≥1 year) | Pre-exposure/post-exposure prophylaxis for humans (mainstream choice) |
| Genetically Engineered Vaccine | Recombinant rabies virus glycoprotein (G protein) | 0.5ml/vial, 1ml/vial | High purity, mild side effects, short production cycle | Pre-exposure/post-exposure prophylaxis for humans (new preferred option) |
| Attenuated Live Vaccine (Veterinary) | Attenuated rabies virus (e.g., SAD strain) | 5ml/bottle, 10ml/bottle | Strong immunogenicity, low cost | Mass immunization of animals such as dogs and cats |
Common Questions and Solutions
Is it still useful to get vaccinated more than 24 hours after being bitten by a dog?
Yes! As long as no symptoms occur, get vaccinated as soon as possible. For severe exposure, rabies immunoglobulin (RIG) should be injected simultaneously—do not give up vaccination due to delayed timing.
Is it normal to experience redness, swelling, or low-grade fever after vaccination?
These are normal local/systemic reactions (incidence rate: approximately 10%-20%), which usually subside on their own within 1-2 days without special treatment. Seek medical attention immediately for high fever or allergies.
Can pregnant or lactating women be vaccinated?
Yes! Rabies vaccines (inactivated or genetically engineered) have no adverse effects on fetuses or infants. Prioritize vaccination in case of exposure.
Can rabies occur after completing the vaccination?
It is extremely rare (e.g., virus latency before vaccination, severe exposure without RIG). The protection rate exceeds 99% after standardized vaccination.
If a pet has been vaccinated, do I still need to get vaccinated if scratched by it?
Yes! The protection rate of animal vaccines is not 100%, and virus carriage cannot be completely ruled out. Follow the post-exposure vaccination procedure.
If you have any further needs or inquiries, please feel free to contact us via international@aimbio.com
AIM Honesty Biopharmaceutical Co., Ltd., which owns the RECVAX® brand, is a Recombinant Hepatitis B Vaccine Hansenula Polymorpha manufacturer from China. We use advanced technology to provide safe and reliable vaccine products for people of all ages, effectively protecting against hepatitis.
What is Hepatitis B?
Hepatitis B is a viral liver disease. Without prevention, approximately 5% to 10% of infected individuals will develop chronic liver disease, increasing their lifelong risk of cirrhosis or liver cancer. It is a very threatening disease. Hepatitis B vaccination has few side effects and effectively protects recipients, so timely vaccination is recommended.
Liver Cancer Prevention
Hepatitis B vaccination is a primary preventive measure for the etiology of liver cancer!
Chronic HBV infection is the most important cause of liver cancer in our country, with about 85% of liver cancer patients carrying HBV. According to WHO, in 2019 there were approximately 296 million people worldwide with chronic HBV infection, and about 820,000 people died from liver failure, cirrhosis, or primary liver cancer caused by HBV infection.
The "Expert Consensus on Primary Prevention of Liver Cancer in China" in 2018 pointed out that after excluding factors such as age and gender, compared with those who are both HBsAg and HBeAg negative, the relative risk of liver cancer for those who are HBsAg positive is 9.6, and for those who are both HBsAg and HBeAg positive, the relative risk is 60.
Immunization is the most economical and effective means to control and even eradicate infectious diseases!
Our Product
Subsidiary of AIM Vaccine, AIM Honesty Biopharmaceutical Co., Ltd. independently developed RECVAX® Recombinant Hepatitis B Vaccine (Hansenula Polymorpha).
Due to the adoption of the first domestic and internationally leading recombinant Hansenula Polymorpha expression technology platform and patented adjuvant technology, it has achieved excellent immune effects, even surpassing the same dose of imported products and even the domestic multiple-dose products.
Product Introduction
AIM Honesty RECVAX®
[Composition and Description]
This product is prepared by purifying hepatitis B virus surface antigen (HBsAg) expressed by recombinant Hansenula Polymorpha yeast and adding aluminum adjuvant. It is a milky white suspension that can be layered due to precipitation and easily shaken and dispersed.
Active ingredient: hepatitis B virus surface antigen.
Excipients: aluminum hydroxide, sodium chloride.
[Vaccinated subjects]
This vaccine is indicated for hepatitis B susceptible individuals, especially those who: (1) Newborns, especially mothers, are HBsAg and HBeAg positive. (2) Medical staff engaged in medical work and laboratory personnel exposed to blood.
[Actions and Usage]
Vaccination stimulates immunity against the hepatitis B virus. Used for prevention of hepatitis B.
[Regulation]
0.5 ml per vial (vial), 0.5 ml per human dose, containing 10μg or 20ug HBsAg.
[Immunization procedures and doses]
(1) was injected intramuscularly into the deltoid muscle of the upper arm.
(2) The immunization schedule is three doses, administered at 0, 1, and 6 months, and newborns receive the first dose of vaccine within 24 hours of birth, one dose each time.
[Adverse reactions]
Common adverse reactions: Pain and tenderness may be felt at the injection site within 24 hours after vaccination and disappear spontaneously within 2 to 3 days in most cases.
Rare adverse reactions:
(1) Transient febrile reactions may occur in vaccinees within 72 hours after vaccination and generally persist for 1 to 2 days and resolve spontaneously.
(2) Mild to moderate redness, swelling and pain at the inoculation site. Generally, it lasts for 1 to 2 days and resolves spontaneously without treatment.
Very rare adverse reactions:
(1) Induration may occur at the inoculation site and is generally absorbed spontaneously in 1 to 2 months.
(2) Local aseptic suppuration: Pus is generally repeatedly aspirated with a syringe, and in severe cases (ulceration) it is necessary to expand the wound to remove necrotic tissue, which lasts longer and can finally be absorbed and healed.
(3) Allergic reactions: allergic rash, Arthur reaction. Arthur reaction generally appears about 10 days after inoculation, local redness and swelling lasts for a long time, and solid alcohols can be used for systemic and local treatment.
(4) Anaphylactic shock: It generally occurs within 1 hour after injection of the vaccine and should be treated with timely injection of epinephrine and other rescue measures.
[Do not avoid]
(1) Known hypersensitivity to any component of the vaccine, including excipients, formaldehyde, and yeast.
(2) Patients suffering from acute diseases, severe chronic diseases, acute attacks of chronic diseases and fever;
(3) Pregnant women.
(4) For uncontrolled epilepsy and other progressive neurological diseases;
[Precautions]
(1) Use with caution in patients with the following conditions: family and individual history of convulsion, chronic diseases, history of epilepsy, and allergic constitution.
(2) It should be shaken well when used, and should not be used if there are clots that do not disperse, foreign bodies, cracks in the vaccine bottle, or unclear labels.
(3) Vaccine bottles should be used immediately when opened.
(4) Drugs such as epinephrine should be available for emergency use in case of occasional severe allergic reactions. Those receiving the injection should be observed in the field for at least 30 minutes after the injection.
(5) If abnormal conditions such as high fever and convulsion occur after the first injection, the second injection is generally no longer injected, and for infants with maternal and fetal blocking, the second and third injections should be followed by the doctor 's advice.
(6) Freezing is strictly prohibited.
[Package and Storage]
Store and transport at 2-8℃, protected from light.
Package Container: The inner packing materials are vials, ampoules and prefilled syringes, vials: 0.5 ml × 1 vials/box, 0.5 ml × 3 vials/box, 0.5 ml × 30 vials/box; ampoules: 0.5 ml × 3 vials/box, 0.5 ml × 9 vials/box; prefilled syringes: 0.5ml × 1 vial/box.
Effective period: Vials: 36 months, ampoules: 24 months, prefilled syringes: 36 months.
Product Specification
Compared to other technical routes, RECVAX® were produced with a more rigorous pharmacopeia standard, which improve the quality and safety of the product.
| Pharmacopoeia Item | Endotoxin content | Free formaldehyde | Thiocyanate | Residual amount of antibiotics | Residual amount of bovine serum albumin |
| Hansenula polymorpha | Less than 5 EU/ml | Less than 15 µg/ml | Not applicable | Not applicable | Not applicable |
| Saccharomyces cerevisiae | Less than 5 EU/ml | Less than 20 µg/ml | Should be less than 1 µg/ml | Not applicable | Not applicable |
| CHO cells | Less than 10 EU/ml | Less than 50 µg/ml | Not applicable | No more than 50 ng/dose | No more than 50 ng/dose |
Characteristic Comparison
| Process | Hansenula Yeast | Saccharomyces Yeast | CHO Cell |
| Process Description | Most advanced process | First generation yeast expression system | Most dated process |
| Tumorigenic Risk? | No | No | Yes |
| Antibiotic Added? | No | No | Yes |
| Bovine Serum Albumin Added? | No | No | Yes |
| Animal Pathogen Risk? | No | No | Yes |
| Thiocyanate Added? | No | Yes | No |
| Immunogenicity | High | Higher | Not much (general double dose vs. yeast shows poor response) |
| Vaccine Purity | Highest | Higher | More additives, lower purity |
| Potential Benefit | Strongest cellular immunity induction | Second strongest cellular immunity induction | Weakest cellular immunity induction |
| Representative Product Statement | 10 µg applicable to all populations | 10 µg applicable only to children | 10 µg immunogenicity poor, almost discontinued |
Product Application
RECVAX® patented adjuvant technology, through in situ adsorption technology, creates an "antigen bank" in the body after the product enters, steadily releasing antigens, extending the duration of antigen action, playing a role in enhancing the stimulation of the immune response, and improving immunogenicity.
The RECVAX® series Hepatitis B Vaccine Hansenula Polymorpha has been on the market for 20 years, covering 31 provinces, cities, and autonomous regions in the country, with a total market usage of nearly 500 million doses, providing immunization plans for nearly 80% of the country's newborns.
A study led by Academician Li Lanjuan evaluated booster immunization in 5- to 15-year-old children with four different hepatitis B vaccines. After a 0-1-6-month booster series with 10 μg RECVAX® (Hansenula-yeast) vaccine, the anti-HBs seropositive rates at 1, 5, and 8 years post-booster reached 83.4 %—the highest among all four vaccines evaluated.
Professional and modern production workshops are the cornerstone of high-quality products!
AIM Vaccine is a professional Hepatitis A Inactivated Vaccine Diploid Cell manufacturer and supplier in China, we apply advanced technology; during the years, we continuously expand our pipeline of products, as we have strong production and innovation abilities.
What is Hepatitis A vaccine?
The hepatitis A vaccine is an inactivated viral vaccine that stimulates the body to produce protective antibodies against the hepatitis A virus (HAV), preventing infection and the development of hepatitis A.
It is typically administered as a 2-dose series (initial dose + a booster 6–12 months later) for long-term immunity, and is recommended for children, travelers to high-risk regions, and individuals with increased exposure risk to HAV.
Why do we need vaccines specifically for hepatitis A?
Hepatitis A vaccines are essential because the hepatitis A virus (HAV) causes acute liver infection with potentially severe symptoms (jaundice, liver damage, even fulminant hepatitis in high-risk groups), and it spreads easily via fecal-oral route (contaminated food/water, close contact) with no specific cure for the infection.
Vaccination is the most effective way to build long-term active immunity against HAV, preventing infection, stopping the virus from spreading in communities, and eliminating the risk of life-threatening liver complications—especially for children, the elderly, and people with pre-existing liver disease who are more vulnerable to severe HAV outcomes.
What’s differences between Inactivated hepatitis A vaccine and Live attenuated hepatitis A vaccine?
| Vaccine characteristics | Inactivated HAV | Live attenuated HAV | Inactivated VS Live attenuated |
| Detox evidence | No biosafety issues | The possibility of atavistic virulence of the virus in vivo has not been ruled out, and the feces of the vaccinators were detoxicated | Safer: non-toxic force atavism |
| Chronic liver disease, immunocompromised patients | Could use | For use with caution/forbidden | Safer: Fewer contraindication |
| Liver injury | Does not replicate in the liver, good safety | Contains live viruses that replicate in liver cells and may cause mild liver enzyme abnormalities | Safer: It does not replicate in the liver |
Elaborate on the advantages of the hepatitis A vaccine produced by AIM Action
The human diploid hepatitis A vaccine produced by AIM Action Biopharmaceutical Co., Ltd. — the inactivated hepatitis A vaccine (human diploid cells) — uses the internationally recognized safe human diploid cells (KMB17) as the culture medium, eliminating the potential viral contamination and tumorigenic risks associated with animal-derived cells. It represents an advanced and next-generation vaccine production technology that is purer and safer.
Core Features: Human-derived Cell-based Safety Assurance
1. Purity, Eliminating Animal Origin Risks: Manufactured from human diploid cells, this vaccine completely avoids potential unknown pathogens or xenogeneic proteins introduced by animal cells such as chicken embryos or hamster kidneys, ensuring purity from the source.
2. Safety record excellence: Human diploid cell matrix has been safely used worldwide for decades, widely used in high-end vaccines such as rabies, chickenpox, etc., and its safety has been clinically validated over a long period of time.
3. The immune response is more natural: The virus is cultured in human cells, and its antigen structure is closer to the shape recognized by the body during natural infection, which may induce a more balanced and lasting immune protection.
4. Wider applicability: With its high safety profile, it provides a vaccination option for a wider range of people, including those with immunocompromised status, without the concern of animal-derived allergies.
AIM Action’s hepatitis A inactivated vaccine, was listed on June 1, 2003, is one of the first inactivated vaccine manufacture to occupy the market in China.
After more than 20 years, AIM Action HAV has been tested and made a positive contribution to the elimination of viral hepatitis in China.
This vaccine offers precise dosing for both adults (over 15 years old) and children (1-15 years old including 15 years old). After completing two full doses, it induces long-term or even lifelong protective antibodies, effectively blocking viral transmission.
Hepatitis A Vaccine for Children
Engineered for children's delicate constitution and rapidly developing immune systems, the inactivated hepatitis A vaccine (human diploid cell) produced by AIM Action Biopharmaceutical Co., Ltd.（The wholly-owned subsidiary of AIM Vaccine Co., Ltd.）delivers a 0.5ml pediatric-specific dose (containing 320EU of hepatitis A virus antigen), achieving optimal balance between safety and immune efficacy. Utilizing internationally certified human diploid cell culture and inactivation technology, it provides long-lasting protection for children of 1-15 years old (including 15 years old).
[Drug Name]
Generic name: Hepatitis A Vaccine (Human Diploid Cell), Inactivated
[Components and Description]
The inactivated hepatitis A vaccine is a preparation made from hepatitis A virus (HAV) LV8 strain grown in human diploid cell KMB17 strain. After cultivation and harvest, the virus suspension Is purified and inactivated. A quantity of aluminum adjuvant is added to make the vaccine. It is a slightly milky-white suspension. Stratified precipitate may form which can be dispersed by shaking.
Active constituent: Inactivated hepatitis A virus.
Excipients: Aluminum hydroxide, 2-phenoxyethanol, glycine,sodium hydrogen sulfite, sodium hydroxide, and phosphate buffered saline (PBS).
[Eligibles]
Hepatitis A-susceptible individuals aged 1-15 years old (including 15 years old).
[Action and Use]
The product can induce immunity against hepatitis A virus in recipients following immunization. It is used to prevent hepatitis A.
[Strength]
0.5ml per vial or syringe, 0.5ml per single human dose for children, containing 320EU of hepatitis A virus antigen.
[Administration and Dosage]
(1) Shake well before use. Inject single human dose im.at deltoid insertion area of the lateral upper arm.
(2) Eligibles of 1-15 years old (including 15 years old) should be administered the pediatric dose, A single dose of vaccine is used for primary immunization, and 1 dose of vaccine for booster immunization at 6 months interval. Each dose is 0.5 ml.
[Storage]
Store and ship the product at 2-8℃, protected from light.
[Packaging]
This product is packaged in a pre-filled syringe or vial , with 1 vial or syringe per small box.
[Validity Period]
36 months.
Hepatitis A Vaccine for Adult
The AIM Action Adult Hepatitis A Vaccine is a preventive product specifically optimized for the immune system characteristics of individuals over 15 years old. Unlike pediatric formulations, this product contains 640EU of hepatitis A virus antigen per 1.0ml. This clinically validated dosage effectively stimulates the adult body to produce sufficient and long-lasting protective antibodies. Adults face relatively higher exposure risks due to work stress, frequent social interactions, and increased travel. With a focus on "strong protection and convenient administration," the vaccine provides a reliable "liver insurance" through a two-dose regimen (0 and 6 months), seamlessly integrating health protection into modern life.
[Drug Name]
Generic name: Hepatitis A Vaccine (Human Diploid Cell), Inactivated
[Components and Description]
The inactivated hepatitis A vaccine is a preparation made from hepatitis A virus (HAV) LV8 strain grown in human diploid cell KMB17 strain. After cultivation and harvest, the virus suspension Is purified and inactivated. A quantity of aluminum adjuvant is added to make the vaccine.It is a slightly milky-white suspension. Stratified precipitate may form which can be dispersed by shaking.
Active constituent: Inactivated hepatitis A virus.
Excipients: Aluminum hydroxide,2-phenoxyethanol, glycine,sodium hydrogen sulfite, sodium hydroxide, and phosphate buffered saline(PBS).
[Eligibles]
Hepatitis A-susceptible individuals aged over 15 years old (excluding 15 years old).
[Strength]
1.0 ml per syringe, 1.0 ml per single human dose for adult, containing 640 EU of hepatitis A virus antigen.
[Administration and Dosage]
(1) Shake well before use. Inject single human dose IM at the deltoid insertion area of the lateral upper arm.
(2) Eligibles over 15 years old (excluding 15 years old) should be given the adult dose, with 1 dose of vaccine for initial immunization and 1 dose of vaccine for booster immunization at 6-month intervals. Each dose is 1.0 ml.
AIM Persistence Biopharmaceutical Co., Ltd. is the manufacturer of Meningococcal Vaccine and a reliable partner with strong R&D capabilities, making it a worthy long-term collaborator. Our vaccine provides protection against four types of infections with a single dose, effectively preventing complex infection scenarios and offering more comprehensive protection.
What is ACYW135 Meningococcal Polysaccharide Vaccine?
ACYW135 Meningococcal Polysaccharide Vaccine is a preventive biological product used to prevent epidemic cerebrospinal meningitis (referred to as "meningitis").
Its core function is to resist the invasion of Neisseria meningitidis of four serogroups A, C, Y, and W135, build a comprehensive immune protection barrier for susceptible groups, and reduce the incidence rate, severe cases and mortality of meningitis.
Hazards of Meningitis
Epidemic cerebrospinal meningitis is an acute respiratory infectious disease caused by Neisseria meningitidis, which is mainly transmitted directly through droplets such as coughing and sneezing, with patients and carriers as the source of infection.
The disease has an acute onset and rapid changes, which can lead to death within 24 hours after the onset in severe cases. Even if cured, some patients may leave sequelae such as brain damage, hearing loss and mental retardation, which are extremely harmful to human health, especially the growth and development of children and adolescents.
Core Product Information
AIM Persistence - Xin'er Cong®
Ingredients and Properties This product is made from the culture fluid of Group A, C, Y, and W135 Neisseria meningitidis, and the capsule polysaccharide antigens are extracted and purified separately, mixed, and then freeze-dried with lactose as a stabilizer. It is a white fluffy substance, and after reconstituted with the provided diluent, it becomes a colorless and clear liquid.
Active ingredients: Each human dose of this vaccine contains 50pμg of polysaccharide from Group A, C, Y, and W135 capsules.
Excipients: Each human dose contains 10.0mg of lactose.
Vaccine diluent: Sterile and pyrogen-free PBS.
Vaccination Target
At present, it is only recommended for use in high-risk populations of children over 2 years old and adults in the following scope:
1. Those who travel to or live in high-risk areas, such as the African meningitis belt (epidemic areas of Group A, C, Y, and W135 Neisseria meningitidis).
2. Those who may come into contact with Group A, C, Y, and W135 Neisseria meningitidis from the air in laboratory or vaccine production work.
3. High-risk populations in areas where the national health administrative departments predict an outbreak of Group Y and W135 Neisseria meningitidis infection based on epidemiological investigations.
Packaging specifications
| Name | Package Size(cm) | |||||
| Box Size | ||||||
| Quantity | Length | Width | Height | Volume | Weight | |
| Group ACYW135 Meningococcal Polysaccharide Vaccine | 200 | 37.8 | 22.3 | 23 | 0.02 | 4.55 |
Advantages of Xin'er Cong®
Xinercong® is a core vaccine brand under AIM Persistence Biopharmaceutical Co., Ltd. Since the launch in China, our ACYW135 Meningococcal Polysaccharide Vaccine has become a trusted preferred brand in the market with strict quality control, advanced production technology.
The core advantages are reflected in the following aspects:
● Multiple serotypes: It can prevent meningococcal meningitis caused by the four dominant serogroups A, C, Y, and W135;
● High seroconversion rate: The seroconversion rates of antibodies in the four meningococcal serogroups A, C, Y, and W135 were all over 96%;
● Long validity period: The only meningococcal product with a validity period of 36 months;
● Low residue rate: No antibiotics or any preservatives are added during the production process.
Professional and modern production workshops are the cornerstone of high-quality products!
Marketing Authorization Holder/Manufacturer: AIM Persistence Biopharmaceutical Co., Ltd.
Registered Address/Production Address: No. 29 Zhuquan Road, Science and Technology Industrial Park, Ninghai County, Ningbo City, Zhejiang Province
Contact us: If you have any further needs or inquiries, please feel free to contact us via international@aimbio.com!
Featured Products
Top Sellers: High-purity Recombinant Hepatitis B Vaccine, Freeze-Dried Rabies Vaccine, and ACYW135 Meningococcal Vaccine, etc. – all available for bulk procurement with factory-direct pricing.
Rabies Vaccine Vero Cell, manufactured by AIM Honor (Ningbo) Biopharmaceutical Co., Ltd., boasts core advantages such as high-titer antigen, a 100% antibody seroconversion rate within 14 days, and low impurity residue. It contains no preservatives or antibiotics, ensuring excellent safety and stability. As a leading vaccine manufacturer in China, we utilize domestically developed, highly effective aG virus strains and advanced intramuscular injection formulations. We support bulk purchasing and cross-border supply, guaranteeing stable supply.
Welcome to choose AIM Honesty Biopharmaceutical Co., Ltd. from China as your Hepatitis B Vaccine supplier. Our vaccines are safe and effective, utilizing a domestically pioneered and internationally leading recombinant Pichia pastoris expression technology platform and patented adjuvant technology. They are suitable for infants, children, and adults.
AIM Action Biopharmaceutical Co., Ltd. (a wholly-owned subsidiary of AIM Vaccine Co., Ltd.) is a manufacturer and supplier of Adult Hepatitis A Vaccine, offering a precise antigen content of 640 EU/ml. The vaccine utilizes a safe human diploid cell culture and inactivation process, providing a highly effective and rapid antibody response.
You can confidently choose the ACYW135 meningococcal polysaccharide vaccine manufactured by AIM Persistence Biopharmaceutical Co., Ltd. We are a leading vaccine manufacturer in China, with the brand name Xin'er Cong®. Our vaccine offers multiple serotypes, a high seroconversion rate, low residual levels, and a long shelf life. It contains no preservatives or antibiotics, ensuring excellent product safety!
Who We Are?
AIM Vaccine: Your Trusted Vaccine Manufacturer & Supplier in China
AIM Vaccine (stock code: 06660) is a listed company on the main board of the Hong Kong Stock Exchange. In terms of industrial scale, it has become the second largest and the largest private full industrial chain vaccine group in China. As a top-tier private vaccine group with a full industrial chain, we operate four state-licensed factories and three R&D hubs across China.
We are one of only two Chinese enterprises with a P3 laboratory—a strategic asset under China's 14th Five-Year Plan. Globally, we are the largest hepatitis B vaccine manufacturer and the second-largest rabies vaccine producer.
With over 28 years of expertise, we deliver WHO-aligned vaccines to 31 Chinese provinces and 20+ countries, driving our mission: "Manufacturing high-quality vaccines for global health."
0
Vaccine Sales Experience
0
Exporting Countries
0
State-licensed Factories
0
R&D Hubs
What Do We Do?
Innovative Vaccine Solutions from Factory to Global Supply
Commercialized Vaccines
- Recombinant Hepatitis B Vaccine
- Inactivated Hepatitis A Vaccine
- Freeze-dried Rabies Vaccine
- ACYW135 Meningococcal Vaccine
- 8 total commercialized products
Pipeline Innovations
- Serum-free Rabies Vaccine
- PCV13 (13-valent pneumococcal)
- MCV4 (Meningococcal Conjugate)
- 24 vaccines under development
- Cutting-edge mRNA technology
Global Distribution Network
Powered by four advanced factories—AIM Honesty (Dalian), AIM Honor (Ningbo), AIM Persistence, and AIM Action (Jiangsu)—we leverage cutting-edge platforms (e.g., mRNA technology) to serve 2,000+ disease control centers worldwide.
20%
Southeast Asia
20%
Africa
50%
West/South/Central Asia
10%
South America
Our Team
Expertise-Driven: China's Vaccine Innovators
Our 1,000+ technical staff (70%+ R&D specialists) fuel AIM Vaccine’s leadership. Collaborating with global institutions, our teams master breakthrough technologies:
AIM Honesty Dalian
Pioneers in recombinant Hansenula polymorpha technology (45M-dose/year hepatitis B capacity).
AIM Honor Ningbo
Rabies vaccine experts (22M doses/year, 2nd largest globally).
AIM Persistence Ningbo
Leaders in bacterial vaccines.
AIM Action Jiangsu
It is one of the only two domestic manufacturers of inactivated hepatitis A vaccine.
Certified under GMP, ISO, and China’s "863 Program," our scientists and engineers ensure every vaccine meets global safety standards—turning research into lifesaving solutions.
Why Choose Us?
China's Premier Vaccine Partner: Quality, Scale, Trust
Our Excellence
Expertise
World's Leading hepatitis B vaccine supplier; 20 pipeline products; P3 lab for advanced research.
Authority
HKEX-listed (06660); GMP/ISO-certified factories; gov't partnerships (e.g., Pakistan, Egypt).
Trust
Exports to 20+ countries; 70% market share for key products; 28 years of proven reliability.
Unmatched Capacity
- 4 factories with 100M+ annual doses; end-to-end supply chain.
Innovation Edge
- mRNA tech leader; patents in genetic engineering.
Partner with AIM Vaccine
Partner with AIM Vaccine—a manufacturer dedicated to global health.
Contact our team for reliable, WHO-aligned vaccine solutions from China.
Contact Our TeamGet a Quote
Send Inquiry
Get competitive quotes within 24hrs! Contact our vaccine specialists for bulk orders, MOQ details, agent programs, and comprehensive solutions – leveraging AIM's 2,800+ CDC distribution network for seamless global delivery.
News
Latest Updates: Track AIM's pipeline breakthroughs, exhibition participations, and global health partnerships – insights from China's mRNA vaccine technology leader driving immunization innovation.
2026-11-06
One of the most important concerns after an incident is understanding when a Dog Bite Vaccine is necessary, how quickly treatment should begin, and what steps can help prevent serious complications. Knowing the correct procedures can make a critical difference in protecting your health.
read more
2026-10-12
A bacterial meningitis vaccine helps protect against specific bacteria that can cause meningitis, a serious infection affecting the membranes surrounding the brain and spinal cord.
read more
2026-08-19
Dog‑transmitted rabies accounts for the overwhelming majority of human rabies cases across rabies‑endemic regions worldwide. Exposure incidents such as dog bites create urgent clinical scenarios requiring timely and appropriate biological intervention to block viral progression toward fatal neurological disease. Freeze‑Dried Rabies Vaccine Vero Cell for Human Use is an inactivated lyophilized cell‑culture vaccine deployed widely for post‑exposure prophylaxis following animal bite events.
read more
2026-07-30
This analysis explores public health value of ACYW135 Meningococcal Polysaccharide Vaccine, a quadrivalent immunization against four major meningococcal strains. The content examines invasive meningococcal disease risks, vaccine immune mechanisms, eligible populations, comparison with alternative vaccines, safety data and worldwide deployment strategies.
read more
2026-07-29
A-Type Meningitis Vaccine plays a critical role in preventing meningococcal disease caused by Neisseria meningitidis serogroup A. As meningitis outbreaks continue to threaten vulnerable populations worldwide, understanding vaccine protection, production standards, immunization strategies, and supplier reliability has become increasingly important. This comprehensive guide explains how the A-Type Meningitis Vaccine works, why it matters, what challenges healthcare organizations face, and how professional vaccine manufacturers such as AIM VACCINE CO., LTD. support global disease prevention efforts.
read more
2026-07-17
Meningococcal disease prevention requires advanced vaccine technology that can address different bacterial serogroups and support effective immune responses. The ACYW135 Meningococcal Polysaccharide Vaccine is designed to provide immune protection against four important meningococcal serogroups, including A, C, Y, and W135. Understanding its scientific principles, manufacturing procedures, quality management systems, and healthcare applications provides valuable insight into modern immunization strategies.
read more
2026-07-17
Understanding hepatitis A prevention requires a comprehensive approach that combines scientific research, vaccine development, quality control, and public health awareness. The Anti-Hepatitis A Virus Vaccine plays an important role in helping individuals develop immune protection against hepatitis A virus infection through advanced biological technology and carefully controlled manufacturing processes.
read more
2026-07-10
Viral hepatitis remains one of the most significant public health challenges worldwide, and vaccination continues to be the most effective strategy for preventing infection, reducing transmission, and protecting vulnerable populations. Hepatitis A Inactivated Vaccine Diploid Cell represents a well-established immunization option built on years of virological research, cell-culture technology, and clinical safety monitoring.
read more
2026-07-10
Chronic hepatitis B virus infection remains a leading global public health crisis that drives irreversible liver damage and high mortality rates across all age demographics. This article unpacks the core technical, clinical and public health advantages delivered by Recombinant Hepatitis B Vaccine Hansenula Polymorpha, alongside comparative analysis against traditional yeast and cell culture vaccine platforms. It explores long-term immunogenicity data, standardized vaccination schedules, safety profiles, and population-wide disease prevention value, focusing on primary liver cancer intervention without commercial financial metrics.
read more
2026-06-30
Meningitis remains one of the most serious infectious diseases affecting children worldwide. It can progress rapidly, leading to severe complications such as brain damage, hearing loss, learning disabilities, or even death. The children meningitis vaccine plays a crucial role in preventing these outcomes by building early immunity against multiple strains of meningococcal bacteria.
read more
2026-06-25
C-Type meningococcal disease is one of the most dangerous bacterial infections affecting the human nervous system, capable of progressing rapidly and causing severe complications or even death within hours if untreated. The C-Type meningitis vaccine is designed to protect against Neisseria meningitidis serogroup C, a major strain responsible for invasive meningococcal disease worldwide. This article provides a complete, in-depth exploration of the vaccine, including how it works, who needs it, safety considerations, global vaccination strategies, and practical insights for healthcare decision-making.
read more
2026-06-11
Invasive meningococcal disease, or IMD, develops after infection with Neisseria meningitidis. Most of the time, this bacterium simply lives inside a person’s nasopharynx without triggering any noticeable symptoms. Trouble starts when it spreads into the bloodstream or other normally sterile parts of the body. IMD does not occur all that often, but it comes with a high fatality rate and can leave patients with serious long-term health issues.
read more